BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7537608)

  • 41. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery.
    Möhle R; Murea S; Kirsch M; Haas R
    Exp Hematol; 1995 Dec; 23(14):1535-42. PubMed ID: 8542944
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin's lymphoma.
    Zallio F; Cuttica A; Caracciolo D; Gavarotti P; Bergui L; Giaretta F; Bondesan P; Tassi V; Gallo E; Pileri A; Tarella C
    Ann Hematol; 2002 Aug; 81(8):448-53. PubMed ID: 12224002
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens.
    Vogel W; Kopp HG; Kanz L; Einsele H
    J Cancer Res Clin Oncol; 2002 Jul; 128(7):380-4. PubMed ID: 12136252
    [TBL] [Abstract][Full Text] [Related]  

  • 48. G-CSF during large field radiotherapy reduces bone marrow recovery capacity.
    Pape H; Orth K; Heese A; Heyll A; Kobbe G; Schmitt G; Niederbichler AD; Peiper M; Schwarz A; Boelke E
    Eur J Med Res; 2006 Aug; 11(8):322-8. PubMed ID: 17052967
    [TBL] [Abstract][Full Text] [Related]  

  • 49. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
    Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
    Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Mobilization of circulating hematopoietic stem cells by granulocyte colony stimulating factor after chemotherapy in multiple myeloma].
    Ohler L; Scholten C; Reiter E; Tiefengraber E; Jäger U; Strobl H; Lechner K; Höcker P; Geissler K
    Wien Klin Wochenschr; 1993; 105(20):580-4. PubMed ID: 7505076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF.
    Delamain MT; Metze K; Marques JF; Reis AR; De Souza CA; Lorand-Metze I
    Transfus Apher Sci; 2006 Feb; 34(1):33-40. PubMed ID: 16376618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of enriched CD34+ cells from healthy volunteers and those from patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF).
    Suzuki T; Muroi K; Tomizuka H; Amemiya Y; Miura Y
    Stem Cells; 1995 May; 13(3):273-80. PubMed ID: 7542113
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
    Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
    Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
    Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
    Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.
    Ria R; Gasparre T; Mangialardi G; Bruno A; Iodice G; Vacca A; Dammacco F
    Bone Marrow Transplant; 2010 Feb; 45(2):277-81. PubMed ID: 19584820
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
    Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM
    Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
    Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
    Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum G-CSF levels in patients undergoing G-CSF/chemotherapy mobilized peripheral stem cell harvest and predictors of neutrophil and platelet recovery.
    Maharaj D; Gómez-Marín O; Lewis-Ximenez LL; Riley R; Albarracín C
    Leukemia; 1995 Oct; 9 Suppl 1():S113-7. PubMed ID: 7475301
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparison of the effectiveness of hematopoietic cell mobilization with chemotherapy and filgrastim versus filgrastim alone for autologous transplant in patients with lymphoma.].
    Gutiérrez-Aguirre CH; De la Garza-Salazar F; Cantú-Rodríguez O; González-Llano Ó; Jaime-Pérez JC; Mancias-Guerra C; García-Sepúlveda R; Salazar-Riojas R; Gómez-Almaguer D
    Gac Med Mex; 2016 Oct; 152(Suppl 2):57-65. PubMed ID: 27792717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.